160 related articles for article (PubMed ID: 22948997)
21. [Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD].
Schaal KB; Engler C; Schütt F; Scheuerle A; Dithmar S
Ophthalmologe; 2008 Jun; 105(6):538-43. PubMed ID: 18299845
[TBL] [Abstract][Full Text] [Related]
22. Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
Byun YJ; Lee SJ; Koh HJ
Jpn J Ophthalmol; 2010 Nov; 54(6):571-7. PubMed ID: 21191718
[TBL] [Abstract][Full Text] [Related]
23. Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide.
Jonas JB; Spandau UH; Harder B; Vossmerbaeumer U; Kamppeter BA
Am J Ophthalmol; 2005 Jun; 139(6):1073-9. PubMed ID: 15953439
[TBL] [Abstract][Full Text] [Related]
24. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results.
Gillies MC; Simpson JM; Luo W; Penfold P; Hunyor AB; Chua W; Mitchell P; Billson F
Arch Ophthalmol; 2003 May; 121(5):667-73. PubMed ID: 12742844
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab for peripapillary choroidal neovascular membranes.
Davis AS; Folk JC; Russell SR; Sohn EH; Boldt HC; Stone EM; Mahajan VB
Arch Ophthalmol; 2012 Aug; 130(8):1073-5. PubMed ID: 22893085
[No Abstract] [Full Text] [Related]
26. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment.
Fong KC; Kirkpatrick N; Mohamed Q; Johnston RL
Clin Exp Ophthalmol; 2008 Nov; 36(8):748-55. PubMed ID: 19128380
[TBL] [Abstract][Full Text] [Related]
28. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
Maier M; Feucht N; Huebner M; Lohmann C
Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.
Nguyen QD; Shah SM; Browning DJ; Hudson H; Sonkin P; Hariprasad SM; Kaiser P; Slakter JS; Haller J; Do DV; Mieler WF; Chu K; Yang K; Ingerman A; Vitti RL; Berliner AJ; Cedarbaum JM; Campochiaro PA
Ophthalmology; 2009 Nov; 116(11):2141-8.e1. PubMed ID: 19700196
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization.
Forte R; Cennamo G; Finelli M; Cesarano I; D'Amico G; De Crecchio G; Cennamo G
Acta Ophthalmol; 2010 Dec; 88(8):e305-10. PubMed ID: 20946332
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.
Schmidt-Erfurth U; Eldem B; Guymer R; Korobelnik JF; Schlingemann RO; Axer-Siegel R; Wiedemann P; Simader C; Gekkieva M; Weichselberger A;
Ophthalmology; 2011 May; 118(5):831-9. PubMed ID: 21146229
[TBL] [Abstract][Full Text] [Related]
32. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
Barbazetto I; Saroj N; Shapiro H; Wong P; Freund KB
Retina; 2010 Oct; 30(9):1376-85. PubMed ID: 20683380
[TBL] [Abstract][Full Text] [Related]
33. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
Bakri SJ; Couch SM; McCannel CA; Edwards AO
Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
[TBL] [Abstract][Full Text] [Related]
34. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CAN CATEGORIZE DIFFERENT SUBGROUPS OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Arrigo A; Romano F; Aragona E; Di Nunzio C; Battista M; Bandello F; Battaglia Parodi M
Retina; 2020 Dec; 40(12):2263-2269. PubMed ID: 32032255
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy.
Amaro MH; Roller AB
Arq Bras Oftalmol; 2012; 75(4):273-6. PubMed ID: 23258660
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
[TBL] [Abstract][Full Text] [Related]
37. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
Retina; 2006; 26(9):988-93. PubMed ID: 17151484
[TBL] [Abstract][Full Text] [Related]
38. Choroidal Thickness Changes After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
Minnella AM; Federici M; Falsini B; Barbano L; Gambini G; Lanza A; Caporossi A; Savastano MC
BioDrugs; 2016 Aug; 30(4):353-9. PubMed ID: 27189458
[TBL] [Abstract][Full Text] [Related]
39. Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study.
Saviano S; Leon PE; Mangogna A; Tognetto D
Digit J Ophthalmol; 2016; 22(2):46-53. PubMed ID: 27582675
[TBL] [Abstract][Full Text] [Related]
40. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]